<DOC>
	<DOC>NCT00384176</DOC>
	<brief_summary>The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.</brief_summary>
	<brief_title>First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Clinical Diagnosis of colon or rectal cancer No prior systemic therapy for metastatic disease. Any adjuvant/neoadjuvant oxaliplatin therapy must have been received &gt;12 months prior to study entry and adjuvant/neoadjuvant 5FU must have been received &gt;6 months prior to study entry. Prior treatment with a VEGF Inhibitor, including bevacizumab and cediranib. Poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>RECENTIN</keyword>
</DOC>